DK3406264T3 - Sammensætning omfattende GLP-1-receptoragonist og glucagonreceptoragonist og anvendelse deraf - Google Patents

Sammensætning omfattende GLP-1-receptoragonist og glucagonreceptoragonist og anvendelse deraf Download PDF

Info

Publication number
DK3406264T3
DK3406264T3 DK16881214.7T DK16881214T DK3406264T3 DK 3406264 T3 DK3406264 T3 DK 3406264T3 DK 16881214 T DK16881214 T DK 16881214T DK 3406264 T3 DK3406264 T3 DK 3406264T3
Authority
DK
Denmark
Prior art keywords
receptor agonist
glp
composition
glucagon
glucagon receptor
Prior art date
Application number
DK16881214.7T
Other languages
English (en)
Inventor
Wei Lv
Min Xu
Yinghui Zhang
Xiaosu Luo
Original Assignee
Pegbio Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pegbio Co Ltd filed Critical Pegbio Co Ltd
Application granted granted Critical
Publication of DK3406264T3 publication Critical patent/DK3406264T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/2278Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/26Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
DK16881214.7T 2015-12-29 2016-12-28 Sammensætning omfattende GLP-1-receptoragonist og glucagonreceptoragonist og anvendelse deraf DK3406264T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201511017796.2A CN106938050B (zh) 2015-12-29 2015-12-29 包含glp-1受体激动剂和胰高血糖素受体激动剂的组合物及其用途
PCT/CN2016/112674 WO2017114425A1 (zh) 2015-12-29 2016-12-28 包含glp-1受体激动剂和胰高血糖素受体激动剂的组合物及其用途

Publications (1)

Publication Number Publication Date
DK3406264T3 true DK3406264T3 (da) 2022-02-28

Family

ID=59225546

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16881214.7T DK3406264T3 (da) 2015-12-29 2016-12-28 Sammensætning omfattende GLP-1-receptoragonist og glucagonreceptoragonist og anvendelse deraf

Country Status (12)

Country Link
US (1) US10894076B2 (da)
EP (1) EP3406264B1 (da)
JP (1) JP6901652B2 (da)
KR (2) KR20200016403A (da)
CN (4) CN113456820B (da)
AU (1) AU2016383387C1 (da)
DK (1) DK3406264T3 (da)
ES (1) ES2912251T3 (da)
GB (1) GB2562407A (da)
RS (1) RS63168B1 (da)
RU (1) RU2719144C2 (da)
WO (1) WO2017114425A1 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113456820B (zh) 2015-12-29 2023-09-08 派格生物医药(苏州)股份有限公司 包含glp-1受体激动剂和胰高血糖素受体激动剂的组合物及其用途
CN110452390B (zh) * 2018-05-03 2021-04-06 清华大学深圳研究生院 一种胰岛素智能给药制剂
CN108841007B (zh) * 2018-06-14 2020-12-29 江南大学 带有羟胺基的艾塞那肽类似物及其应用
CN115845031A (zh) * 2021-09-24 2023-03-28 派格生物医药(苏州)股份有限公司 一种含有聚乙二醇化艾塞那肽变体的药物组合物及其用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1959986B1 (en) * 2005-11-07 2014-07-23 Indiana University Research and Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
CN101790538B (zh) 2007-02-15 2014-07-30 印第安纳大学研究与科技公司 胰高血糖素/glp-1受体共激动剂
PA8830501A1 (es) * 2008-06-17 2010-07-27 Univ Indiana Res & Tech Corp Co-agonistas del receptor de glucagon/glp-1
TWI541023B (zh) 2008-06-17 2016-07-11 印第安納大學科技研究公司 在生理ph緩衝液中呈現增強之溶解度及穩定性之升糖激素類似物
CN101870728A (zh) * 2009-04-23 2010-10-27 派格生物医药(苏州)有限公司 新型Exendin变体及其缀合物
WO2010144508A1 (en) * 2009-06-08 2010-12-16 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
WO2011163473A1 (en) * 2010-06-25 2011-12-29 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability in physiological ph buffers
US20130137645A1 (en) 2010-07-19 2013-05-30 Mary S. Rosendahl Modified peptides and proteins
KR101382593B1 (ko) * 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
EP2694095B1 (en) * 2011-04-05 2018-03-07 Longevity Biotech, Inc. Compositions comprising glucagon analogs and methods of making and using the same
CA2837710C (en) * 2011-06-02 2022-11-08 Prolor Biotech Inc. Pegylated oxyntomodulin conjugates with improved linkers
US9309301B2 (en) * 2011-06-22 2016-04-12 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
ES2636445T3 (es) * 2011-06-22 2017-10-05 Indiana University Research And Technology Corporation Coagonistas de receptores de glucagón/GLP-1
KR101357117B1 (ko) * 2011-06-28 2014-02-06 비앤엘델리팜 주식회사 폴리에틸렌글라이콜 또는 이의 유도체로 페길화된 엑센딘-4 유사체, 이의 제조방법 및 이를 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학적 조성물
AU2013226090B2 (en) 2012-02-27 2018-03-08 Amunix Operating Inc. XTEN conjugate compositions and methods of making same
KR102092025B1 (ko) * 2012-06-04 2020-03-24 옵코 바이오로직스 리미티드 페길화된 옥신토모둘린 변이체
TWI617574B (zh) * 2012-12-11 2018-03-11 梅迪繆思有限公司 用於治療肥胖之升糖素與glp-1共促效劑
UA116553C2 (uk) * 2012-12-21 2018-04-10 Санофі Пептидна сполука - агоніст рецептора glp-1 i glp
CN104277104A (zh) * 2013-07-08 2015-01-14 派格生物医药(苏州)有限公司 包含聚合物和生物活性分子的缀合物及其用途
US9932381B2 (en) * 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
CN113456820B (zh) 2015-12-29 2023-09-08 派格生物医药(苏州)股份有限公司 包含glp-1受体激动剂和胰高血糖素受体激动剂的组合物及其用途

Also Published As

Publication number Publication date
WO2017114425A1 (zh) 2017-07-06
GB2562407A (en) 2018-11-14
KR20180096785A (ko) 2018-08-29
JP6901652B2 (ja) 2021-07-14
US10894076B2 (en) 2021-01-19
EP3406264A4 (en) 2019-07-17
KR20200016403A (ko) 2020-02-14
AU2016383387A1 (en) 2018-07-12
CN113456802A (zh) 2021-10-01
ES2912251T3 (es) 2022-05-25
RS63168B1 (sr) 2022-05-31
RU2018127330A (ru) 2020-01-31
EP3406264A1 (en) 2018-11-28
US20190134161A1 (en) 2019-05-09
CN113456820B (zh) 2023-09-08
CN113546159B (zh) 2023-09-08
JP2019500399A (ja) 2019-01-10
RU2719144C2 (ru) 2020-04-17
CN113456820A (zh) 2021-10-01
CN106938050A (zh) 2017-07-11
EP3406264B1 (en) 2022-02-16
CN106938050B (zh) 2021-08-24
AU2016383387C1 (en) 2020-01-23
AU2016383387B2 (en) 2019-09-19
RU2018127330A3 (da) 2020-01-31
CN113546159A (zh) 2021-10-26
GB201811757D0 (en) 2018-08-29

Similar Documents

Publication Publication Date Title
DK3555064T3 (da) GLP-1 receptoragonister og anvendelser deraf
DK3806855T5 (da) GLP-1-receptoragonister og anvendelser deraf
DK3806955T3 (da) GLP-1-receptoragonister og anvendelser deraf
IL285231A (en) Co-agonistic compounds for glucagon and glp-1
IL260318A (en) A triple agonist for glucagon/glp-1/gip receptors
IL251741A0 (en) Co-agonists for glucagon and 1- glp receptors
DK3350165T3 (da) Farnesoid-X-receptoragonister og anvendelser deraf
DK3596053T3 (da) Farnesoid-x-receptoragonister og anvendelser deraf
ZA201802371B (en) Glucagon receptor agonists
DK3357513T3 (da) Farmaceutisk sammensætning og anvendelse deraf
MA50474A (fr) Co-agonistes à action prolongée des récepteurs du glucagon et du glp-1
EP3394091A4 (en) CO-AGONISTS OF GLUCAGON AND GLP-1 RECEPTORS
EP3377521A4 (en) LONG-ACTING CO AGONISTS OF GLUCAGON AND GLP-1 RECEPTORS
DK3406264T3 (da) Sammensætning omfattende GLP-1-receptoragonist og glucagonreceptoragonist og anvendelse deraf